Extended Data Figure 6: Immunophenotyping in rIL33-treated PDAC mice.

(a) Percent tumor establishment of orthotopic and subcutaneous KPC-OVA PDAC tumors in vehicle (veh) and rIL33 treated mice. (b) Gating (left) and frequency (right) of IL18R1 expression on tumor ILCs in subcutaneous (SQ) and orthotopic PDAC mice. (c) Gating (left) and frequency (right) of splenic ILC2s following rIL33 treatment in orthotopic PDAC mice. (d) Gating (left) and frequency (right) of tumor ILC2s following rIL33 treatment in subcutaneous PDAC mice. (e) Gating (left) and frequency (right) of cytokine and PD-1 expression on tumor CD8⁺ T cells following rIL33 treatment in orthotopic PDAC mice. (f) Frequency of immune cells in vehicle- and rIL33-treated orthotopic PDAC mice. (g) Gating strategy for identification of CD103⁺ dendritic cells. (h) Gating (left; tumors) and frequency (right) of ILC2s in tumors and draining lymph nodes (DLN) of wild type (WT) or Rora^fl/fl IL7r^Cre mice (ILC2-deficient) PDAC mice following rIL33 treatment. (i) Gating (left) and frequency (right) of PD-1⁺ CD8⁺ T cells in tumors of rIL33-treated WT and Batf3^−/− mice. Data were collected at 6 (a), 5 (b), and 3 (i) weeks post tumor implantation. Horizontal bars mark medians. n indicates individual mice analyzed separately in at least two independent experiments with n≥2/group. P values determined by two-tailed Mann-Whitney test (a, f, i).